AVI finds new prospects in Seattle cluster

Over the past year AVI Biopharma's fortunes have been transformed. Its stock price has more than tripled as it has pushed new RNA programs for Duchenne Muscular Dystrophy and the Ebola and Marburg viruses. The developer moved from Portland to a new home in the Bothell, WA cluster. And it's raised $50 million from its fattened stock to help continue work that has so far consumed $271 million in R&D costs. "We were one of two healthcare-based companies in Corvallis, and now we're one of 200 in the Bothell area," CEO Les Hudson tells Xconomy. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.